PhotoPharmics
PhotoPharmics is a clinical-stage therapeutic device company developing next-generation treatments for addressing neurodegenerative disorders through the eyes. We have 30 years of experience in product innovation, clinical trials, and market development in specialized phototherapy. We previously developed specialized solutions now widely used to regulate circadian rhythms for seasonal affective disorder, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007). Our main focus is Parkinson’s, and we are extending our research into several other neurodegenerative diseases. We aim to make a clinically meaningful difference in patients’ lives by delivering safe and effective treatments. PhotoPharmics is privately held and is raising a Series B equity round to fund the Celeste Light for Parkinson’s pivotal trial.
Domain
photopharmics.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$6.0M
Founded
2010
Tech Stack (26 technologies)
Frequently Asked Questions
What technologies does PhotoPharmics use?+
PhotoPharmics uses 26 technologies including Divi, Google Analytics, Google Tag Manager.
What industry is PhotoPharmics in?+
PhotoPharmics operates in the Biotechnology industry.
Where is PhotoPharmics based?+
PhotoPharmics is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026